Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025
- New clinical data from the MATCH Phase II study shows early improvement in liver function after treatment with non-engineered macrophages is associated with positive long term clinical outcomes
- New preclinical data from Resolution’s first engineered Regenerative Macrophage Therapy, RTX001, shows significant reduction of systemic inflammation
- Comes as Resolution progresses its Phase I/II EMERALD study of RTX001 in patients with end-stage liver disease
Edinburgh and London, UK, 7 November 2025 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, today announces new clinical and preclinical data strongly supporting the hypothesis that Regenerative Macrophage Therapy (RMT) has anti-inflammatory and anti-fibrotic effects in cirrhosis. The data will be presented in two separate poster presentations during the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting® 2025, taking place in Washington D.C. from 7 to 11 November 2025.
